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Background: Extranodal natural killer/T-cell lymphoma (ENKL) has heterogeneous clinical manifestations and
prognosis. This study aims to evaluate the prognostic impact of absolute monocyte count (AMC) in ENKL, and
provide some immunologically relevant information for better risk stratification in patients with ENKL.
Methods: Retrospective data from 163 patients newly diagnosed with ENKL were analyzed. The absolute monocyte
count (AMC) at diagnosis was analyzed as continuous and dichotomized variables. Independent prognostic factors
of survival were determined by Cox regression analysis.
Results: The AMC at diagnosis were related to overall survival (OS) and progression-free survival (PFS) in patients
with ENKL. Multivariate analysis identified AMC as independent prognostic factors of survival, independent of
International Prognostic Index (IPI) and Korean prognostic index (KPI). The prognostic index incorporating AMC and
absolute lymphocyte count (ALC), another surrogate factor of immune status, could be used to stratify all 163
patients with ENKL into different prognostic groups. For patients who received chemotherapy followed by
radiotherapy (102 cases), the three AMC/ALC index categories identified patients with significantly different
survivals. When superimposed on IPI or KPI categories, the AMC/ALC index was better able to identify high-risk
patients in the low-risk IPI or KPI category.
Conclusion: The baseline peripheral monocyte count is shown to be an effective prognostic indicator of survival in
ENKL patients. The prognostic index related to tumor microenvironment might be helpful to identify high-risk
patients with ENKL.
Keywords: Absolute monocyte count, Extranodal natural killer/T-cell lymphoma, Prognosis, Tumor
microenvironmentBackground
Extranodal nasal-type natural killer/T-cell lymphoma
(ENKL) is a rare lymphoid neoplasm characterized by a
cytotoxic phenotype. It is associated with Epstein–Barr
virus (EBV) infection, vascular destruction, and obvious
necrosis [1,2]. Its incidence is low in western populations
but more prevalent in Latin America and East Asia, in-
cluding China [3-5]. ENKL in China accounts for approxi-
mately 5–16% of all lymphoid neoplasms [5-8]. Patients* Correspondence: lzmlzmlzm@yahoo.com
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reproduction in any medium, provided the orwith ENKL have heterogeneous clinical manifestations
and prognosis [9,10]. Using the International Prognostic
Index (IPI), nearly 80% of ENKL cases were categorized as
low-risk, although some patients in this category have a
poor prognosis [11]. Therefore, more and more studies
are trying to find novel prognostic markers or another
index, such as the Korean prognostic index (KPI), to better
stratify patients with ENKL based on risk [12].
Immune system deficiency is a risk factor for non-
Hodgkin lymphomas (NHL) [13,14]. Gene-expression pro-
filing studies show an interaction between the host
immune system and lymphoma [15-17]. Lymphopenia, a
surrogate factor of immune status, is reported to be anLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics of 163 patients with
extranodal nasal-type natural killer/T-cell lymphoma
(ENKL) at diagnosis
Characteristics Number of patients %






≥ 2 12 7.4
Serum LDH > 245 u/l 55 33.7
B symptoms 85 52.1














AMC ≥ 0.50×109/L 118 72.4
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance
status; LDH, lactate dehydrogenase; UNKTL, upper aerodigestive tract NK/T-cell
lymphoma; EUNKTL, extraupper aerodigestive tract NK/T-cell lymphoma; KPI,
Korean Prognostic Index; IPI, International Prognostic Index; AMC, absolute
monocyte count.
a Complete data on regional lymph node involvement was available in
138 patients.
b Complete data on KPI prognostic score was assessable in 138 patients.
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plasms [18-22]. In the recent preclinical studies, monocytes
are found to be plentiful in the tumor microenvironment
and contribute to the growth of malignant T-cells [23].
Monocytes have also been found to induce the proliferation
of natural killer (NK)/T lymphoma cells and to infiltrate
lymphomas [24]. Recent evidence shows a relationship be-
tween peripheral monocyte count (another immunologic-
ally relevant marker) and survival in patients with diffuse
large B-cell lymphoma (DLBCL) and follicular lymphoma
(FL) [25,26]. To the best of our knowledge, the prognostic
impact of absolute monocyte count (AMC) in NK/T cell
lymphoma has never been assessed. The current study was
performed to investigate the prognostic influence of mono-
cytes (another surrogate marker for tumor microenviron-
ment) on survival in ENKL, and provide some information
on host immunity at diagnosis for better risk stratification
in patients with ENKL.
Methods
Ethics statement
This study was approved by the Institutional Review
Board (IRB) of Sun Yat-Sen University Cancer Center.
Study was performed in accord with the principles of
the Declaration of Helsinki. All patients agreed to use
their medical records for research.
Patients and staging
This retrospective study included 163 patients with ENKL
newly diagnosed between January 2001 and December
2009 at the Sun Yat-Sen University Cancer Center of China.
All the cases were pathologically confirmed as extranodal
NK/T-cell lymphoma, nasal type, based on morphologic
and immunophenotypic criteria of the 2001 World Health
Organization (WHO) classification. Cases with blastic NK-
cell lymphoma/leukemia, aggressive NK-cell lymphoma/
leukemia, peripheral T-cell lymphoma, unspecified, or
with negative EBV in situ hybridization, were excluded.
Informed consent was obtained from all patients prior to
treatment.
Information regarding demographics, Eastern Coopera-
tive Oncology Group (ECOG) performance status, physical
examinations, systemic B symptoms, complete blood count
(CBC), biochemical profiles, and serum lactate dehydro-
genase (LDH) level were collected for analysis. The staging
was based on the Ann Arbor staging system. Whole-body
positron emission tomography/computed tomography
(PET/CT) scans, CT scans or magnetic resonance imaging
(MRI) scans of the involved sites, as well as thorax, abdo-
men, and pelvic CT scans, and bone marrow findings were
used for staging. Patients with contiguous involvement
extending to the adjacent tissues or organs were regarded
as stage IE. Upper aerodigestive tract NK/T-cell lymphoma
(UNKTL) and extra- upper aerodigestive tract NK/T-celllymphoma (EUNKTL) were defined as previously de-
scribed [8,27]. The International Prognostic Index (IPI:
stage, ECOG performance status, serum LDH, stage,
extranodal sites) and the Korean Prognostic Index for NK/
T-cell lymphoma with nasal disease (KPI: serum LDH
level, B symptoms, stage, regional lymph nodes involve-
ment) were evaluated as previously described [12,28].
Treatment modalities and response criteria
Patients received one of the following treatments: (i)
chemotherapy followed by radiotherapy; (ii) chemother-
apy alone; (iii) involved-field radiation alone; (iv) surgery
followed by radiation; (v) best supportive care. The first-
line chemotherapy regimens were: EPOCH (etoposide,
Figure 1 Survivals in ENKL stratified by AMC. Overall survival (A) and progression-free survival (B) of all patients (n=163) with ENKL stratified
by the absolute monocyte count (≥0.50×109/L versus < 0.50×109/L) at diagnosis.
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CHOP (cyclophosphamide, doxorubicin, vincristine, and
prednisone) or CHOP-like therapy, alternating triple
therapy (CHOP-B [cyclophosphamide, doxorubicin, vin-
cristine, prednisone, bleomycin], IMVP-16 [ifosfamide,
etoposide, methotrexate], and DHAP [dexamethasone,
cytarabine, cisplatin]), GEMOX (gemcitabine, oxaliplatin)
+/− L-asparaginase, and SMILE (dexamethasone, metho-
trexate, ifosfamide, L-asparaginase, etoposide). Radiother-
apy for the involved-field was given in daily fractions of
2 Gy (five fractions per week) for a total of 36–68 Gy. The
International Working Group Recommendations for Re-
sponse Criteria for non-Hodgkin’s lymphoma were used
to evaluate the treatment response [29].Statistical analysis
Overall survival (OS) and progression-free survival (PFS)
were assessed by the Kaplan–Meier method. OS was cal-
culated from the date of diagnosis to the date of death
from any cause, or date of the last follow-up. PFS was cal-
culated from the date of diagnosis to the date of firstTable 2 Multivariate Cox-regression analysis of variables
related to overall survival in patients with extranodal
nasal-type natural killer/T-cell lymphoma (n=163)




IPI score 2.197 1.415-3.409 <0.001
Abbreviations: AMC, absolute monocyte count; IPI, International
Prognostic Index.lymphoma progression, death from any cause, or date of
the last follow-up [29]. The absolute monocyte count
(AMC) at diagnosis was analyzed as both continuous and
dichotomized parameters. The optimal cut-off values of
the AMC were determined using the receiver operating
characteristics (ROC) method. In the ROC curve analysis,
survival outcomes were dichotomized into death versus
survival. The relationship between AMC (as a dichoto-
mized variable) and clinical parameters was analyzed by
Pearson's χ2 test. Survival curves were constructed using
the Kaplan–Meier method. The prognostic influence of
different parameters on survival was established by multi-
variate analysis using the Cox proportional hazards model.
The two-tailed log-rank test method was used to deter-
mined statistical difference, and P value of less than 0.05
was regarded as statistically significant. Statistical analysis
was carried out by SPSS 16.0 software.
Results
Patients characteristics
The baseline characteristics of all 163 patients with ENKL
are shown in Table 1. The median age at the time ofTable 3 Multivariate Cox-regression analysis of variables
related to progression-free survival in patients with
extranodal nasal-type natural killer/T-cell lymphoma
(n=163)






IPI score 1.728 1.163-2.568 0.007
Abbreviations: AMC, absolute monocyte count; IPI, International
Prognostic Index.
Figure 2 Survivals in ENKL categorized by the prognostic index. Overall survival (A) and progression-free survival (B) of all patients (n=163)
with ENKL categorized by the absolute monocyte and lymphocyte prognostic index. Group 1 (low risk), AMC <0.50×109/L and ALC>1.10×109/L;
Group 2 (intermediate risk), AMC ≥ 0.50×109/L or ALC ≤ 1.10×109/L; Group 3 (high risk), AMC ≥ 0.50×109/L and ALC ≤ 1.10×109/L.
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predominance (113 men and 50 women). Eight-five pa-
tients (52.1%) presented systemic B symptoms, and 55 pa-
tients (33.7%) had elevated serum LDH level prior to
treatment. Nearly 80% of the patients (128 cases) had local-
ized disease (Ann Arbor stage: I-II). Upper aerodigestive
tract NK/T-cell lymphoma (UNKTL) was diagnosed in 140
cases (85.9%) and extra-upper aerodigestive tract NK/T-cell
lymphoma (EUNKTL) in 23 cases (14.1%). For those with
EUNKTL, the most common sites of primary extranodal
involvement were cutaneous or soft tissue (11 cases),
followed by the gastrointestinal tract (5 cases). InternationalFigure 3 Survivals in ENKL with chemotherapy followed by radiother
Progression-free survival (B) of patients received chemotherapy followed b
lymphocyte prognostic index. Group 1 (low risk), AMC <0.50×109/L and AL
1.10×109/L; Group 3 (high risk), AMC ≥ 0.50×109/L and ALC ≤ 1.10×109/L.Prognostic Index (IPI) assessment found that the majority
of the patients (125 cases, 76.7%) were in the low-risk cat-
egory (IPI score = 0–1). The Korean Prognostic Index
(KPI) was assessable in 138 patients with nasal disease. In
the KPI model, 84 patients (60.9%) had no or one adverse
factor, and the remaining 54 patients (39.1%) had at least
two adverse factors.
The AMC were obtained from the complete blood
count (CBC) test prior to treatment. The median AMC at
diagnosis, range, and the 25% and 75% quartiles were
0.60×109/L, 0.05–2.10×109/L, 0.44×109/L, and 0.80×109/L,
respectively. The most discriminative cut-points of theapy categorized by the prognostic index. Overall survival (A) and
y radiotherapy (n=102) categorized by the absolute monocyte and
C>1.10×109/L; Group 2 (intermediate risk), AMC ≥ 0.50×109/L or ALC ≤
Figure 4 Survivals in ENKL with low-risk KPI stratified by the prognostic index. Overall survival (A) and progression-free survival (B) of
patients with low-risk KPI score (KPI score = 0–1, n=84) as determined by the absolute monocyte and lymphocyte prognostic index. KPI, Korean
Prognostic Index. Group 1 (low risk), AMC <0.50×109/L and ALC>1.10×109/L; Group 2 (intermediate risk), AMC ≥ 0.50×109/L or ALC ≤ 1.10×109/L;
Group 3 (high risk), AMC ≥ 0.50×109/L and ALC ≤ 1.10×109/L.
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0.630, 95% confidence interval: 0.534-0.726, P = 0.011), as
determined by receiver operating characteristics (ROC)
analysis. Therefore, AMC ≥0.50×109/L which were close
to the most discriminative cut-points, were selected as the
optimal cut-off values. The most discriminative cut-points
of the ALC were 1.145×109/L (AUC: 0.601, 95% confi-
dence interval: 0.512-0.690, P = 0.027), as determined by
ROC analysis. Therefore, ALC ≤1.10×109/L, which was
close to the most discriminative cut-point, was selected as
the optimal cut-off value. Patients with high AMC at
diagnosis tended to have poorer performance status
(P = 0.002) and IPI >1 (P = 0.022).Survival and prognostic factors
The initial treatment modalities were chemotherapy
followed by radiotherapy (n = 102); chemotherapy alone
(n = 50); surgery followed by radiation (n = 2); radiother-
apy alone (n = 4); and supportive care (n = 5). The data on
evaluation of treatment response to the initial therapy
were available in 151 cases (92.6%). Complete remission
(CR) was observed in 71 patients (47.0%). No statistical
difference was found in the baseline clinical characteristics
between patients with AMC ≥0.50×109/L and those with
AMC <0.50×109/L.
The estimated overall survival (OS) and progression-free
survival (PFS) at 5 years was 43.7% and 33.9%, respect-
ively. Patients with higher AMC level (AMC ≥0.50×109/L,
n = 118) seemed to have shorter OS and PFS (OS:
P = 0.023; PFS: P = 0.016; Figure 1A and B). Univariate
analysis of AMC as a continuous variable also showedAMC to be related to inferior survival (OS: P <0.001;
PFS: P = 0.049). As KPI and IPI are commonly used
prognostic indexes for ENKL, they were included with
AMC in multivariate analysis. As shown in Table 2 and
Table 3, AMC retained their prognostic impact on OS
and PFS in patients with ENKL, independent of IPI
score. KPI score was not found to be an independent
prognostic factor of survival in multivariate analysis.
The AMC/ALC prognostic index identifies high-risk
patients in ENKL
Absolute lymphocyte count (ALC), as an indicator of im-
mune status, was shown to be associated with OS and PFS
in our previous study [19]. However, either AMC or ALC,
as a single parameter, appeared to have limited ability to
identify patients in the poor-risk category. Therefore, we
combined the baseline AMC with the baseline ALC as di-
chotomized variables, to obtain a host immunity-related
prognostic index of survival in patients with ENKL. Re-
garding the AMC/ALC prognostic index as a categorical
variable, all 163 patients were stratified into the following
three risk categories: group 1 (low risk), AMC <0.50×109/L
and ALC>1.10×109/L; group 2 (intermediate risk),
AMC ≥0.50×109/L or ALC ≤1.10×109/L; group 3 (high
risk), AMC ≥0.50×109/L and ALC ≤1.10×109/L. The asso-
ciations between patients’ clinical characteristics and
AMC/ALC prognostic index were evaluated. Patients with
high risk AMC/ALC index seemed to have a higher rate of
B symptoms (P = 0.005). The OS and PFS based on the
AMC/ALC prognostic index for patients with ENKL are
shown in Figure 2. Univariate analysis showed that the
AMC/ALC index allowed the discrimination of the three
Figure 5 Survivals in ENKL with low-risk IPI stratified by the prognostic index. Overall survival (A) and progression-free survival (B) of
patients with low-risk IPI score (IPI score = 0–1, n=125) as determined by the absolute monocyte and lymphocyte prognostic index. IPI, International
Prognostic Index. Group 1 (low risk), AMC <0.50×109/L and ALC>1.10×109/L; Group 2 (intermediate risk), AMC ≥ 0.50×109/L or ALC ≤ 1.10×109/L;
Group 3 (high risk), AMC ≥ 0.50×109/L and ALC ≤ 1.10×109/L.
Huang et al. BMC Cancer 2013, 13:222 Page 6 of 8
http://www.biomedcentral.com/1471-2407/13/222risk groups with a 5-year OS ranging from 74.2% to 23.2%,
P = 0.001 and a 5-year PFS varying from 54.0% to 17.5%,
P = 0.002. For patients who received chemotherapy
followed by radiotherapy (102 cases), the three AMC/ALC
index categories identified patients with significantly differ-
ent survivals (OS: P = 0.006; PFS: P = 0.014; Figure 3).
Moreover, when applied to the patients with low-risk IPI
score (IPI = 0–1) or low-risk KPI score (KPI = 0–1), the
AMC/ALC index identified significantly different prognos-
tic categories in patients with low-risk KPI score (OS:
P = 0.006; PFS: P <0.001; Figure 4) and patients with low-
risk IPI score (OS: P = 0.014; PFS: P = 0.027; Figure 5).
Further stratification by AMC/ALC index category identi-
fied 15 patients (17.9%) in the low-risk KPI score category
and 25 patients (20%) in the low-risk IPI score category as
high risk (5-year OS of 21.0% and 29.7%, respectively).
Discussion
Epidemiologic studies show that immune deficiency in-
creases the risk of NHL [30,31]. The incidence of NHL
was much higher in immunosuppressed individuals than
in non-immunosuppressed individuals [32,33]. Gene-
expression signature studies in patients with B-cell NHL
indicated that the myeloid-lineage cells in the tumor
microenvironment influence the survival outcomes of pa-
tients with DLBCL and FL [15,16]. Monocytes were found
to heavily infiltrate tumor samples from lymphoma pa-
tients, and this infiltration was found to be related to
tumor invasion and immune response suppression in the
animal model of lymphoma [15]. Furthermore, monocytes
were recently found to promote the cell growth andsurvival in T-cell lymphomas and NK/T-cell lymphoma
[23,24]. The predictive role of absolute monocyte count
has been studied in B-cell NHL, as well as some solid tu-
mors [25,26,34-36]. Limited data are available about the
influence of monocytes on the survival of patients with
ENKL. Hence, our study was carried out to evaluate the
relevance of the peripheral blood monocyte count (a sur-
rogate marker of the tumor microenvironment and host
immunity) as a prognostic marker of survival in ENKL.
In this series, relatively elevated AMC at diagnosis
(when treated as a continuous or dichotomized variable)
was related to inferior prognosis. In multivariate ana-
lysis, AMC retained its prognostic impact on survival
outcome in ENKL, and was independent of the conven-
tional prognostic index. Evidence that AMC is an ad-
verse prognostic factor in NHL was recently provided by
Wilcox et al. in patients with DLBCL and FL [25,26].
AMC combined with IPI or Follicular Lymphoma Inter-
national Prognostic Index (FLIPI) score helped to iden-
tify patients with poor prognosis. In patients with some
solid neoplasms such as melanoma, renal cell carcinoma,
and small cell lung cancer, elevated monocytes used as an
immune parameter were also related to unfavorable sur-
vival [34-37]. Myeloid-derived cells (MDCs), including
tumor-infiltrating monocytes and their progeny, were
demonstrated to promote tumor angiogenesis and metas-
tasis by suppressing the host immune response through
regulation of macrophage cytokine production [38]. In
T-cell NHL, many MDCs are found in the tumor micro-
environment. When malignant T cells are co-cultured
with monocytes, the proliferation and growth of tumor
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pleted, malignant T cell death is increased [23]. Similar phe-
nomena are observed in NK/T-cell lymphoma. Monocytes
promote the cell proliferation and growth of EBV-
positive NK/T-cell lymphoma cells, as well as the EBV-
encoded latent membrance protein-1 (LMP-1) expression
and interferon inducible protein-10 (IP-10) production.
These functions of monocytes are mediated by cell contact
dependent interaction via interleukin (IL)-15 [24]. Produc-
tion by NK/T-cell lymphoma cells of IP-10 (a major
chemoattractant of human monocytes) can increase mono-
cyte infiltration of the tumor microenvironment [39-41].
Therefore, there is a positive feedback relationship between
monocytes and lymphoma cells in the microenviroment of
NK/T-cell lymphoma [24].
Lymphocyte count is another surrogate marker of im-
mune homeostasis, and lymphopenia is regarded as an
indicator of immunoincompetence [42]. Lymphopenia
was an independent prognostic factor of adverse survival
in our previous studies [19]. In the current study, our re-
sults showed that monocyte was also helpful to predict
prognosis in ENKL. Therefore, we devised a simple prog-
nostic index related to tumor microenvironment and host
immune status that incorporates both AMC and ALC.
This index was independent of conventional prognostic
indices (such as KPI and IPI) and can be easily applied in
clinical practice. The AMC/ALC index stratified patients
with ENKL into three risk categories with significantly dif-
ferent survival outcomes. The current study and previous
studies showed that the majority of patients with ENKL
have no or one adverse IPI score or KPI score [12,19].
When superimposed on the IPI or KPI score, the AMC/
ALC index provides additional prognostic information.
This novel index was able to identify about 20% of patients
in the low-risk KPI or low-risk IPI score category as high
risk (with an inferior 5-year OS of less than 30%).
The current management of newly diagnosed ENKL
patients was mainly based on the involvement sites (lo-
calized or disseminated disease). In this series, although
most of the ENKL patients with localized disease under-
went chemotherapy combined with radiation, some pa-
tients in this subgroup had unfavorable prognosis. The
AML/ALC index was helpful to identify patients with
poor survival outcomes. Maybe the combined treatment
modality is insufficient to cure the high-risk patients.
Several retrospective studies suggested that high-dose
chemotherapy followed by autologous hematopoietic
stem cell transplantation (HD-AHSCT) showed promis-
ing results for patients with disseminated ENKL
[43-45]. It is interesting to investigate the efficacy of
HD-AHSCT in the high-risk patients with localized dis-
ease in future studies. In this series, the underlying posi-
tive or negative biases during the therapy or selection of
patients were inevitable, due to the limitation of itsretrospective nature. Future prospective studies are
warranted to validate our results.
Conclusion
In conclusion, the baseline monocyte count is helpful to
predict prognosis in ENKL patients. The AMC/ALC
prognostic index, incorporating variables associated with
the tumor microenvironment and host immunity, may
offer a better risk stratification for patients with ENKL,
when superimposed on the IPI or KPI. This finding war-
rants confirmation in independent cohorts. Further in-
vestigation is required to achieve a better understanding
of the mechanism underlying the relationship between
immunology and prognosis in NK/T-cell lymphoma.
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